Changming Xia, Dr.

Associate Director, Statistics
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Poster(s):

• (409) Dupilumab effectiveness through 24 months in patients from the United States with CRSwNP enrolled in the global AROMA registry
  Wednesday, October 29, 2025

• (410) Baseline Characteristics of Patients on Medium-Versus High-Dose Inhaled Corticosteroids in Patients Initiating Dupilumab in a Real-World Clinical Setting: The RAPID Registry
  Wednesday, October 29, 2025